Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

And Ritlecitinib, or Litfulo (Pfizer), was approved for severe alopecia areata in patients 12 years of age and older." ...

In June 2023, Pfizer's LITFULOTM (Ritlecitinib) for Adults and Adolescents with Severe Alopecia Areata received FDA approval. The medication, known by the brand name Litfulo, has been approved for ...

Ritlecitinib is under clinical development by Pfizer and currently in Phase II for Keloids ... role in drug-specific PTSR and likelihood of approval. Ritlecitinib (Litfulo) acts as an ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...

However, at least two conditions listed as adverse events also appeared in Pfizer's 2024 list of genuine side effects. In January 2025, Snopes readers asked us about the authenticity of a long ...

Three students from Centreville High School in Clifton discovered a potentially harmful substance – DNA residues, or tiny fragments of genetic material – in Pfizer’s messenger RNA COVID-19 ...

Pre-market: 4:24:23 am GMT-5 ...

After hours: 7:20:20 p.m. EST ...